Nexstim Plc - first NBT® system for depression ordered in

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
35
Nexstim Plc - first NBT® system for depression ordered in the US

Company announcement, Helsinki, 22 May 2018, at 9:00 AM Nexstim Plc - first NBT® system for depression ordered in the US

Nexstim Plc (NXTMH:HEX, NXTMS:STO) ("Nexstim" or "Company"), the targeted neuromodulation company developing and commercializing its world-leading navigated non-invasive brain stimulation technology for therapeutic and diagnostic applications, announces that it has agreed to deliver its first Navigated Brain Therapy (NBT®) system in the US to Island Psychiatry, a private practice that provides accessible, high quality comprehensive mental healthcare on Long Island, New York.  The placement follows Nexstim's launch of the SmartFocus TM TMS technology at the Clinical TMS (transcranial magnetic stimulation) Society Annual Meeting in New York, which took place from 11-13 May.

Island Psychiatry uses a Unified Specialities Approach that brings a variety of disciplines together to provide appropriate assessment and treatment including TMS for major depressive disorder for each individual patient. TMS is used to stimulate and increase the activity of an area of the brain called the left dorsolateral prefrontal cortex (DLPFC), where metabolic activity is reduced in depression. Island Psychiatry will use the NBT® system to provide patients with personalised navigated TMS therapy.

Nexstim received FDA approval in November 2017 allowing practices like Island Psychiatry to provide patients with personalised navigated TMS therapy. Nexstim's NBT® system is based on its unique SmartFocus TM TMS technology and is the only FDA approved personalised navigation approach for accurate targeted TMS in Major Depressive Disorder (MDD). This is achieved through its 3D navigation system, personalised based on a patient's MRI scan.

Martin Jamieson, Chairman and CEO, Nexstim Plc commented: "We are delighted to announce that Island Psychiatry, a leader in TMS depression therapy in the US, will be the first clinic using our NBT® system in the US. Placing this first system in the US marks an important milestone for us and we look forward to working with the center to generate case studies that highlight the beneficial impact that our personalised approach delivers to patients with depression."

NEXSTIM PLC Martin Jamieson, Chairman and CEO

Further information is available on the website www.nexstim.com or by contacting:

Nexstim                                                                                                                                                                                       Martin Jamieson, Chairman and CEO    +44 77 1516 3942 martin.jamieson@nexstim.com

Sisu Partners Oy (Certified Adviser) +358 (0)10 231 4560

Citigate Dewe Rogerson                 +44 (0)207 2822949 David Dible/Shabnam Bashir/Isabelle Andrews david.dible@citigatedewerogerson.com

About Island Psychiatry Island Psychiatry is a diverse group of mental health practitioners that bring a unified specialties approach to diagnose and treat a broad range of psychiatric disorders in children, adolescents, and adults in the Long Island, New York area. For more information, visit https://islandpsychiatry.com/

About Major Depressive Disorder (MDD) and Navigated Brain Therapy (NBT®) Major Depressive Disorder (MDD) is a recurrent and frequently chronic disorder with significant unmet clinical need. Approximately 10 million Americans suffer from Major Depressive Disorder (MDD) annually and 35% of patients treated with anti-depressant drugs fail to respond to this method of treatment.

Nexstim's NBT® therapy provides personalised non-invasive neuro-stimulation therapy as an alternative to sub-optimal pharmacologic treatments via its SmartFocus TM TMS technology.

About Nexstim Plc Nexstim is a targeted neuromodulation company focused on developing and commercializing its world-leading navigated non-invasive brain stimulation technology, known as SmartFocus TM TMS (transcranial magnetic stimulation), for therapeutic applications, namely stroke, depression and chronic pain via its Navigated Brain Therapy (NBT®) system.

Nexstim has launched its NBT® system in the US for the treatment of Major Depressive Disorder (MDD) following clearance from the FDA for marketing and commercial distribution for this indication. The NBT® system is CE marked in Europe for the treatment of stroke, major depression and chronic neuropathic pain.

The NBT® system is currently in a 60 patient, supplemental Phase III study, E-FIT trial, for its use in stroke rehabilitation. The trial is expected to complete in mid-2018, allowing Nexstim to file for FDA clearance. FDA clearance would allow Nexstim to start marketing and selling its NBT® system for stroke rehabilitation in the US.

In addition, Nexstim is commercialising its Navigated Brain Stimulation (NBS) system for diagnostic applications, based on the same technology. The NBS system is the only FDA cleared and CE marked navigated TMS system for pre-surgical mapping of the speech and motor cortices of the brain.

Nexstim shares are listed on the Nasdaq First North Finland and Nasdaq First North Sweden. For more information please visit www.nexstim.com.

Attachment

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Flagship's £100M London Move to Ignite AI Ventures

Updated Category News Views 201

London Calling: Flagship's New Venture Flagship Pioneering, the brain behind bustling biotech ventures like Moderna, is planting its flag in London. They're launching Flagship Origination Lab, U.K., their first real gig outside good ol' Cambridge, Massachusetts. They're diving in headfirst, sprinkling a whopping £100 million to brew up AI-native platform companies. And...

Continue Reading
Bizzdesign Tops Gartner’s 2026 Enterprise Architecture List

Updated Category News Views 100

Enterprise Architecture’s Silent Backbone Sometimes it's the quiet operators like Bizzdesign that hijack the spotlight after years of steady steering. With the latest nod from Gartner, Bizzdesign is clearly on a tear in the enterprise architecture domain. In their 2026 Critical Capabilities report, Bizzdesign's products—Horizzon, Alfabet, and Hopex—secured top spots...

Continue Reading
PepsiCo Nears Deforestation-Free Sourcing Milestone by 2025

Updated Category News Views 129

PepsiCo's Aim for a Greener Supply Chain Well, look who's climbing the environmental ladder—PepsiCo. They’ve apparently hit 94% deforestation-free sourcing for those high-stakes commodities their empire relies on. Maybe it's a wake-up call for the rest of 'em still smogging about. The endgame? Full-fledged deforestation-free sourcing by 2030. That’s no walk in the...

Continue Reading
Priceline's Cyber Week: A Pocket-Friendly Travel Bonanza

Updated Category News Views 146

Unpacking Priceline's Cyber Week Bonanza Alright, folks, grab your booking hats because Priceline is back with its annual Cyber Week extravaganza, aiming to give travelers a shot in the arm of savings just when inflation has everyone pinching pennies. From November 16 through December 2, Priceline rolls out the red carpet for vacation planners, offering eye-popping...

Continue Reading
New York Reclaims Bagel Crown at 2026 BagelFest

Updated Category News Views 139

A Bagel Victory at Citi Field Holy schmear! New Yorker's are grinning wide like a bagel with a double helping of cream cheese—Ess-a-Bagel from Manhattan snagged the top honors at the heavily contested 2026 New York BagelFest. Back in its rightful hands, the Bagel Crown stays in the Empire State, and it's a victory for tradition and taste. Celebrating 50 years in the...

Continue Reading
Fortvita's Zybrivo Gains CHMP Nod: A European Leap

Updated Category News Views 103

It's not every day you're reading about a biotech making a ground-breaking shift off Chinese shores, but Fortvita's latest breakthrough is worth noting. Their fancy immunotherapy, Zybrivo® (sintilimab), just snagged a nod from the CHMP, Europe's committee that guides many on the medicinal merry-go-round. This isn't just your run-of-the-mill nod either. We're talking...

Continue Reading
YONDELIS: Thai Approval Opens New Sarcoma Treatment Path

Updated Category News Views 254

New Hope for Thai Sarcoma Patients Alright, we’ve got some good news coming out of Thailand, folks. The Thai FDA just greenlit YONDELIS® (trabectedin) for those grappling with advanced soft tissue sarcoma (STS). Now, this isn’t your everyday drug release—it’s a clinical chess move packing potential for patients who’ve run out of other options. December 1st,...

Continue Reading
Exploring Why Dead Outlets Stay Dead: Expert Insights

Updated Category News Views 66

The Mystery of Non-Responsive Outlets Ever found an electrical outlet refusing to cooperate when you need it most? Well, I know the frustration all too well. You'd think if the breaker ain't blown, the outlet should work like a charm. But dive into the guts of the story, and you find a series of surprises waiting to trip us up. Common Culprits: Tripped GFCIs and Loose...

Continue Reading
Baidu's Q3 2026: AI Explodes Amid Marketing Slump

Updated Category News Views 35

Baidu Looks to AI as Revenue Driver in Q3 2026 You know, Baidu's got one heck of a story this quarter. Despite some clouds hanging over them, they’ve managed to find a silver lining in their AI ventures. It’s like they’ve got this magic bullet with AI Cloud growth skyrocketing 94% year over year. That’s not just a rabbit outta the hat; it’s more like pulling a...

Continue Reading
MacKenzie-Childs Grinds Into Spotlight with Oprah's Nod

Updated Category News Views 50

Oprah's Golden Touch: 30 Years Strong Every year, there are a few select spots that brands covet like a hawk on a rabbit hunt. Getting on Oprah’s 'Favorite Things' list is surely one of them. Just like that, the MacKenzie-Childs Electric Salt and Pepper Grinder Set has muscled its way into the 2026 selection. Spare me the bells and whistles; this is like hitting the...

Continue Reading

Top 5 Most Recently Viewed Articles

Citi Raises Price Target for Blackstone Amid Encouraging Outlook

Updated Category News Views 131

Citi's Updated Outlook on Blackstone Recently, Citi revisited its financial forecast for The Blackstone Group (NYSE: BX), adjusting the price target upward from $157.00 to $170.00 while maintaining a Neutral stance on the stock. This update follows the company's impressive third-quarter performance, which saw Blackstone's stock rise by 6.3% post-earnings announcement....

Continue Reading
JAB's Strategic Acquisition of Mondelez Shares in JDE Peet's

Updated Category News Views 92

JAB's Significant Move in the Coffee Industry In a strategic and noteworthy development, JAB has made headlines by agreeing to acquire a substantial share package from Mondelez, focusing on Dutch coffee giant JDE Peet's. This major transaction amounts to approximately €2.2 billion, or about $2.4 billion. JAB intends to purchase 86 million shares at a price of €25.10...

Continue Reading
Urgent Update for DXC Technology Company Investors

Updated Category News Views 272

DXC Technology Company (NYSE: DXC) found itself in hot water back in 2024 when shareholders raised hell over alleged falsehoods that inflated stock prices. The Rosen Law Firm rolled out a class action lawsuit aimed at those who bought shares during what they dubbed the Class Period—a time rife with questionable operational claims from DXC's brass. Allegations Surface:...

Continue Reading
Investigation Launched: National Grid Faces Legal Scrutiny

Updated Category News Views 283

Bragar Eagel & Squire, P.C. Initiates Investigation Bragar Eagel & Squire, P.C., a well-regarded law firm known for advocating for investors, has begun an investigation surrounding concerns related to National Grid plc (NYSE: NGG). This inquiry primarily aims to assist stockholders who may have experienced losses while owning shares of National Grid. The firm invites...

Continue Reading
Oil & Gas Sector Trends: Path to 8.79 Trillion Growth

Updated Category News Views 223

Oil & Gas Market Growth and Projections The global oil and gas market has positioned itself for remarkable expansion. With estimates currently valuing the market at approximately USD 6.10 trillion, projections suggest it could soar to around USD 8.79 trillion by 2034. This growth translates to a compound annual growth rate (CAGR) of 3.72% between 2025 and 2034. Notably,...

Continue Reading